Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sotigalimab - Pyxis Oncology

Drug Profile

Sotigalimab - Pyxis Oncology

Alternative Names: APX 005; APX 005M; EPI-0050; PYX-107

Latest Information Update: 05 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Epitomics
  • Developer Arcus Biosciences; Bristol-Myers Squibb; Parker Institute for Cancer Immunotherapy; Pyxis Oncology; University of California at San Francisco; University of Texas M. D. Anderson Cancer Center; University of Texas Southwestern Medical Center; Yale University
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Apoptosis stimulants; CD40 antigen stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Soft tissue sarcoma; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Rectal cancer; Soft tissue sarcoma
  • Phase I/II Non-small cell lung cancer
  • No development reported Brain cancer; Glioma; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 22 Dec 2023 Apexigen terminates a phase II trial in Malignant melanoma (Metastatic disease, Inoperable/Unresectable) in Poland and Spain (IV) based on a business decision (NCT04337931)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease) in USA (IV, Infusion)
  • 28 Oct 2023 No recent reports of development identified for phase-I development in Rectal cancer(Combination therapy, First-line therapy) in USA (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top